BARD1 Antibody (E-11): sc-74559

BARD1 Antibody (E-11) is a mouse monoclonal IgG1 kappa light chain antibody that detects BARD1 of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). BARD1 (E-11) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. BARD1 plays a crucial role in DNA damage repair and is essential for maintaining genomic stability, which is vital for preventing tumorigenesis. Located in the nucleus, BARD1 interacts with BRCA1, forming a complex that is integral to the ubiquitin-proteasome pathway, thereby regulating the degradation of proteins involved in cell cycle control and apoptosis. Mutations in BRCA1, located on chromosome 17q, are associated with a significant increase in the risk of early-onset breast and ovarian cancers, with BARD1 serving as a potential tumor suppressor. BARD1 consists of an N-terminal RING domain, which is critical for E3 ubiquitin ligase activity, and three ankyrin repeats that facilitate protein-protein interactions. Additionally, the C-terminus of BARD1 contains a BRCT domain that shares homology with BRCA1, further underscoring BARD1′s role in DNA repair mechanisms. Anti-BARD1 antibody (E-11) is an invaluable tool for researchers studying the molecular pathways of cancer and the intricate interactions between tumor suppressor proteins.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

BARD1 Antibody (E-11) References:

1. Familial breast-ovarian cancer locus on chromosome 17q12-q23.  |  Narod, SA., et al. 1991. Lancet. 338: 82-3. PMID: 1676470
2. Common non-synonymous polymorphisms in the BRCA1 Associated RING Domain (BARD1) gene are associated with breast cancer susceptibility: a case-control analysis.  |  Huo, X., et al. 2007. Breast Cancer Res Treat. 102: 329-37. PMID: 17028982
3. Linkage of early-onset familial breast cancer to chromosome 17q21.  |  Hall, JM., et al. 1990. Science. 250: 1684-9. PMID: 2270482
4. The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.  |  Tarsounas, M. and Sung, P. 2020. Nat Rev Mol Cell Biol. 21: 284-299. PMID: 32094664
5. The Function of BARD1 in Centrosome Regulation in Cooperation with BRCA1/OLA1/RACK1.  |  Otsuka, K., et al. 2020. Genes (Basel). 11: PMID: 32722046
6. Computational structural assessment of BReast CAncer type 1 susceptibility protein (BRCA1) and BRCA1-Associated Ring Domain protein 1 (BARD1) mutations on the protein-protein interface.  |  Thirumal Kumar, D., et al. 2022. Adv Protein Chem Struct Biol. 130: 375-397. PMID: 35534113
7. BRCA1 mutations in primary breast and ovarian carcinomas.  |  Futreal, PA., et al. 1994. Science. 266: 120-2. PMID: 7939630
8. Breast cancer gene offers surprises.  |  Nowak, R. 1994. Science. 265: 1796-9. PMID: 8091205
9. Identification of a RING protein that can interact in vivo with the BRCA1 gene product.  |  Wu, LC., et al. 1996. Nat Genet. 14: 430-40. PMID: 8944023
10. Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains.  |  Jin, Y., et al. 1997. Proc Natl Acad Sci U S A. 94: 12075-80. PMID: 9342365
11. Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers.  |  Thai, TH., et al. 1998. Hum Mol Genet. 7: 195-202. PMID: 9425226
12. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression.  |  Jensen, DE., et al. 1998. Oncogene. 16: 1097-112. PMID: 9528852

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-BARD1 Antibody (E-11) has 14 citations in a variety of scientific publications.

Primary antibodies like Anti-BARD1 Antibody (E-11) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

BARD1 Antibody (E-11) Specifications

Alternate Product Name: BRCA1 Associated RING Domain 1

Product Clone Name: E-11

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 1-300

Epitope Target: BARD1

Epitope Species: human

Product Reactivity/Detection: BARD1

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 14 citations in various scientific publications

Available Conjugates/Forms for BARD1 Antibody (E-11): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin